Chief Medical Officer
Dr. Fowler, who was a resident in Internal Medicine and Pediatrics at Wayne State University, completed the Medical Oncology Fellowship at the National Cancer Institute, NIH in Bethesda, MD. After fellowship, he worked in the NCI to study the role of Th1/Th2 regulation of transplantation responses, including graft rejection, GVHD, and graft-versus-tumor (GVT) responses. As a tenured Senior Investigator at the NCI in the Experimental Transplantation and Immunology Branch, he maintained both a laboratory effort and a clinical translational effort, where he served as Principal Investigator on clinical trials evaluating various autologous and allogeneic immune therapies. Dr. Fowler’s lab pioneered the use of ex vivo rapamycin to generate rapamycin-resistant T cells, which in a phase II clinical trial performed in the allogeneic stem cell transplantation setting were found to be safe and associate with a low rate of GVHD, stable mixed chimerism, and GVT effects in patients with refractory hematologic malignancy. After a 27-year career at the NIH, Dr. Fowler started a T cell therapy company in Rockville, MD, RAPA Therapeutics, LLC. RAPA Therapeutics is a clinical-stage biotechnology company with two main foci: first, the use of rapamycin-resistant Th1/Tc1 cells for the therapy of cancer, with the initial clinical trial being a phase II study in relapsed, refractory multiple myeloma (clinicaltrials.gov; NCT04176380); and second, the use of rapamycin-resistant hybrid TREG/Th2 cells for the therapy of neuro-degenerative and auto-immune diseases, with the initial clinical trial being a phase I study in patients with amyotrophic lateral sclerosis (clinicaltrials.gov; NCT04220190).